Oculis Holding AG Warrants (OCSAW) Stock Price
OCSAWStock
$4.79
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.27
OCSAW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-64.16%
Price vs S&P 500 (4W)-4.93%
VGM Score10.78
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OCSAWOculis Holding AG Warrants | — | — | F | $4.79 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Oculis Holding AG Warrants
Oculis Holding AG is a biopharmaceutical company developing targeted therapies for eye diseases and vision disorders. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmologic conditions including glaucoma and diabetic retinopathy. The company employs topical and disease-modifying approaches to address significant unmet needs in ophthalmology.